GEMCITABINE HETERO gemcitabine (as hydrochloride) 200 mg powder for injection vial

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

gemcitabine hydrochloride, Quantity: 228 mg

Commercializzato da:

Hetero Australia Pty Ltd

INN (Nome Internazionale):

Gemcitabine hydrochloride

Forma farmaceutica:

Injection, powder for

Composizione:

Excipient Ingredients: sodium hydroxide; mannitol; sodium acetate trihydrate

Via di somministrazione:

Intravenous Infusion

Confezione:

1 vial

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

Gemcitabine is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine is also indicated for patients with 5-FU refractory pancreatic cancer.,Gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.,Gemcitabine, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy

Dettagli prodotto:

Visual Identification: White to off-white lyophilised powder to be reconstituted for intravenous use.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2015-03-03